Release – Voyager Digital Appoints Chief Technology Officer

 


Voyager Digital Appoints Chief Technology Officer

 

Company’s new CTO, Rakesh Gidwani, to lead platform and system expansion

Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG; OTCQX: VYGVF; FRA: UCD2) one of the fastest-growing, publicly traded cryptocurrency platforms in the United States, today announced the appointment of Rakesh Gidwani as the Company’s Chief Technology Officer.

Rakesh joins Voyager from Two Sigma Investments, a technology and data-driven financial services company applying artificial intelligence, machine learning, and distributed computing to investing. At Two Sigma, Rakesh served as Senior Vice President of Engineering, leading the engineering strategy, planning, and technical program management for Two Sigma Investment Management. Rakesh has experience building and scaling high-calibre teams in hyper-growth environments. Over his career, he successfully led engineering teams to deliver eCommerce solutions, high-performance trading systems, financial compliance and risk management systems, and customer-facing websites.

Rakesh will lead the evolution of Voyager’s platform and systems as the Company continues its plans for international expansion and growing to 10+ million customers. He will work closely with Voyager’s CEO Steve Ehrlich, as well as Dan Costantino, Voyager’s Chief Information Security Officer, and Oscar Salazar, Co-founder and advisor to Voyager who served as Uber’s founding Architect and CTO.

“Rakesh is a highly-accomplished engineering leader that we’re excited to have on the Voyager team,” said Steve Ehrlich, Co-founder and CEO of Voyager. “He has a track record from both innovative tech startups and large, established companies, having held senior engineering positions at Goldman Sachs, Morgan Stanley, and Walmart. We welcome Rakesh to our growing team as we position Voyager to expand internationally and add new features to our platform, including traditional financial products and equities.”

Rakesh’s hire is a continuation of Voyager’s accelerated growth as the Company scaled 800% in the past year to currently over 225 full-time employees and executives.


About Voyager Digital Ltd.
Voyager Digital Ltd. (TSX: VOYG; OTCQX: VYGVF; FRA: UCD2) is a fast-growing, publicly traded cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 60 different crypto assets using its easy-to-use mobile application, and earn rewards up to 12 percent annually on more than 30 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides crypto payment solutions for both consumers and merchants around the globe. To learn more about the company, please visit https://www.investvoyager.com.

The TSX has not approved or disapproved of the information contained herein.

SOURCE Voyager Digital, Ltd.


Press Contacts

Voyager Digital, Ltd.
Michael Legg
Chief Communications Officer
(212) 547-8807
mlegg@investvoyager.com

Voyager Public Relations Team
pr@investvoyager.com

QuickChek – September 29, 2021



Voyager Digital Appoints Chief Technology Officer

Voyager Digital announced the appointment of Rakesh Gidwani as the Company’s Chief Technology Officer

Research, News & Market Data on Voyager Digital

Watch recent presentation from Voyager Digital



Capstone Green Energy Supports Mexican Commercial and Industrial Sector’s Self-Generation Demand with a C800S Microturbine System

Capstone Green Energy announced that it has secured an order from DTC Ecoenergía (www.dtc.mx), Capstone’s exclusive distributor for Mexico, for a 5-bay C800 Signature Series microturbine system

Research, News & Market Data on Capstone Green Energy

Watch recent presentation from Capstone Green Energy



Russ Hauth Retires from Salem and Nic Anderson Takes on Director, Government Relations Responsibilities

Salem Media Group announced that following a 34-year relationship with Salem, Russ Hauth will retire October 22, 2021

Research, News & Market Data on Salem Media

Watch recent presentation from Salem Media



Avivagen Inc. Announces Results for the Third Quarter Ending July 31, 2021

Avivagen announced its unaudited financial results for the third quarter of 2021

Research, News & Market Data on Avivagen

Watch recent presentation from Avivagen



Kratos Receives Approximate $50 Million, Single Award, Sole Source High Performance Jet Drone System Related IDIQ Contract

Kratos Defense & Security Solutions announced it has recently received an approximate $50 million, single award, sole source, high performance jet drone system related Indefinite Delivery, Indefinite Quantity (IDIQ) contract

Research, News & Market Data on Kratos

 

Stay up to date. Follow us:

 

Release – Russ Hauth Retires from Salem and Nic Anderson Takes on Director Government Relations Responsibilities


Russ Hauth Retires from Salem and Nic Anderson Takes on Director, Government Relations Responsibilities

 

IRVING, Texas–(BUSINESS WIRE)– Salem Media Group, Inc. (NASDAQ: SALM) announced today that following a 34-year relationship with Salem, Russ Hauth will retire October 22, 2021. In his time with Salem, Russ served as SVP, heading up National News and Public Affairs. He also served for many years as Executive Director of the National Religious Broadcasters Music License Committee and was Salem’s chief negotiator on music licensing related issues. In more recent years Russ has directed Salem’s Office of Government Relations.

Minneapolis General Manager Nic Anderson will take on Government Relations duties in addition to his continuing role as GM. Nic is active with Minneapolis Broadcasters Association (“MBA”), an active participant in the state leadership conference and in July of this year was hand-selected by the MBA to travel to Washington DC as part of a fly-in where he represented the MBA, Salem, and the National Association of Broadcasters. Nic has a deep passion and talent in this area, and he understands the unique aspects of Salem which impact our strategies and how we communicate inside and outside of the beltway. Plus, “It’s always good to reward talented people inside the company when new opportunities arise,” said David Santrella, Salem’s President of Broadcast Media.

ABOUT SALEM MEDIA GROUP:

Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at www.salemmedia.comFacebook and Twitter.

Evan D. Masyr
Executive Vice President and Chief
Financial Officer
(805) 384-4512
evan@salemmedia.com

Source: Salem Media Group

Release – Capstone Green Energy Supports Mexican Commercial and Industrial Sectors Self-Generation Demand with a C800S Microturbine System

 


Capstone Green Energy (NASDAQ:CGRN) Supports Mexican Commercial and Industrial Sector’s Self-Generation Demand with a C800S Microturbine System

 

Capstone’s Shipped Fleet to Mexico Stands in Excess of 68 Megawatts.

VAN NUYS, CA / ACCESSWIRE / September 29, 2021 / Capstone Green Energy Corporation (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN), a global leader in carbon reduction and on-site resilient green energy solutions, announced today that it has secured an order from DTC Ecoenergía (www.dtc.mx), Capstone’s exclusive distributor for Mexico, for a 5-bay C800 Signature Series microturbine system.

“The demand for high-efficiency cogeneration in Mexico is rapidly growing, due in part to the increase in energy demand and the tightening of environmental policies,” said Alejandro Muñoz, President of DTC Ecoenergía. “The solution offered by DTC through Capstone Green Energy has had an positive reception by the Mexican market, due to its efficiency in reducing polluting emissions, as well as its performance in reducing energy costs. All this translates to environmental and economic savings for users, while obtaining high-quality power and supply reliability.” He added, “We save the environment and our customer’s pockets.”

The agreement increases Capstone’s shipped fleet to Mexico to over 68 Megawatts (MW), of which 58 percent of DTC’s installed fleet is covered under a service contract, and reflects a growing need for reliable, cost-effective energy generation in the country. According to Mexico’s National Electrical System Development Program (Programa de Desarrollo del Sistema Eléctrico Nacional or PRODESEN), Mexico’s total generation capacity as of April 2021 reached 89,479 MW. This represented an increase of 7.6 percent over 2020. Of that amount, a total of 35.5 percent was from clean energy sources (renewable and non-renewable, such as nuclear and efficient cogeneration). Looking ahead, the International Energy Agency predicts that Mexico’s population will grow to over 150 million by 2050, predictably increasing energy demand, particularly in the industrial and commercial sectors, that accounts for 72 percent of overall electricity demand.

One of the core challenges faced by the manufacturing industry is the need for highly reliable energy solutions that not only reduce operational costs and increase reliability but also support sustainability goals. Capstone’s scalable on-site energy efficiency systems are engineered to meet the large electrical and thermal demand requirements of industrial manufacturers, delivering energy independence with higher operational efficiency than the local utility grid. A Combined Heat & Power (CHP) system supported by a five-bay Capstone C800S package is designed to provide both 24/7 reliable and continuous electrical power and thermal energy for processes and operations.

Utilizing the heat by-product from a microturbine allows facilities to reduce emissions and save added costs that would otherwise be required to produce heat or steam in a separate unit. While traditional electricity from the grid with coal and gas-fired plants produces power at 33% efficiency, Capstone CHP systems can reach efficiencies of more than 80%.

“This is an important inflection point for energy companies like Capstone Green Energy that can provide innovative, reliable, distributed power solutions,” said Darren Jamison, President and Chief Executive Officer of Capstone Green Energy. “DTC has been a key partner for Capstone in offering their customers our highly reliable, low-emission technology that not only supports their environmental goals but also helps lower their energy costs while ensuring minimal downtime and production losses,” concluded Mr. Jamison.

About Capstone Green Energy

Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Conversion Products are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Products business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen Energy Solutions, Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: rentals@CGRNenergy.com. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three years are estimated at 1,115,100 tons of carbon and $698 million in annual energy savings.

For more information about the Company, please visit: www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on TwitterLinkedInInstagramFacebook, and YouTube.

Cautionary Note Regarding Forward-Looking Statements

This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations for green initiatives and execution on the Company’s growth strategy and other statements regarding the Company’s expectations, beliefs, plans, intentions, and strategies. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT:
Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
ir@CGRNenergy.com

SOURCE: Capstone Green Energy Corporation

Release – Avivagen Inc. Announces Results for the Third Quarter Ending July 31 2021


Avivagen Inc. Announces Results for the Third Quarter Ending July 31, 2021

 

• Total of 8 tonnes in orders secured or shipped during the quarter
• Quarter represents more than 43% of 2020 fiscal year

Ottawa, ON /Business Wire/ September 29, 2021/ Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the third quarter of 2021.

“The considerable successes of the past quarter have resulted in arguably the strongest pipeline in Avivagen’s history,” says Kym Anthony, Chief Executive Officer, Avivagen Inc. “We have already begun to deliver on the largest sales volumes in company history, and efforts worldwide are forging high-value relationships with new partners and customers in the Americas and Asia.”

Q3 2021 highlights included:

  • Total of 8 tonnes in OxC-beta™ orders secured or shipped during the quarter
    • Secured a 4.4-tonne order for OxC-betaTM Livestock from UNAHCO
    • Secured a 500 kg order for OxC-betaTM Livestock from Transformadora
    • Shipped 3.5-tonne order from the previously announced 64-tonne recurring order
  • Moved closer to regulatory approval in Vietnam and China
  • Leveraging existing experience, initiated search for new distribution partners in North America and other key markets globally

During the quarter Avivagen shipped the first 3.5 tonnes of its previously announced 64 tonne recurring order. However, the revenue on this shipment will be recognized when payment is received, meaning the revenue associated with this shipment is not reflected in the reported Q3 results.

Third Quarter: July 31, 2021, Financial Results

The Company’s unaudited Financial Statements for the third quarter ended July 31, 2021 and the accompanying Management’s Discussion and Analysis have been filed on the System for Electronic Document Analysis and Retrieval and are also available via its website (www.sedar.com).  The financial information for the third quarter ended July 31, 2021, should be read in conjunction with the Company’s unaudited Financial Statements as well as its Management’s Discussion and Analysis for the third quarter ended July 31, 2021.

The Company reported revenues of $505,886 ($612,530 in the quarter ending July 31, 2020) and a comprehensive loss of $(1,503,665) for the quarter ending July 31, 2021. This compares to a comprehensive loss in the quarter ending July 31, 2020 of $(787,424).

As at July 31, 2021, the Company reported total assets of $4,865,220 (current assets of $4,569,978), total liabilities of $7,456,993, and shareholders’ deficit of ($2,591,773).

Significant financing inflows during the nine-month ending July 31, 2021, was an offering of 15,000,000 units of the Company at $0.50 per unit for aggregate gross proceeds of $7,500,000. The offering closed on February 16th, 2021.

Each unit consisted of one common share in the capital of the Company (each a “Common Share”) and one half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will be exercisable to acquire one Common Share until February 16, 2024 at an exercise price of $0.75 per share. The net proceeds of the Offering have been and will be used to fund research and development expenses, sales and marketing costs, product registration, interest expense, working capital and general corporate purposes.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions aim”, anticipate”, appear”, believe”, consider”, could”, estimate”, expect”, if”, intend”, goal”, hope”, likely”, may”, plan”, possibly”, potentially”, pursue”, seem”, should”, whether”, will”, would” and similar expressions. Statements set out in this news release relating to Avivagen’s pipeline, its expectations as to future growth, demand for products and results, the anticipated future value of relationships being established, the anticipated continuation of shipments to customers based on recurring orders,  the planned use of proceeds of the financing discussed above,   the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded and the size of market opportunities are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, initial orders may not result in new orders for Avivagen’s products,  despite receipt of the purchase order timing, delivery or  fulfilment of orders of product could be delayed for a number of reasons, some of which are outside of Avivagen’ s control, which could result in anticipated revenues from such sales being delayed or in the most serious cases eliminated, actions taken by Avivagen’ s customers and factors affecting the business and financial viability of Avivagen’ s customers can have a negative impact on the expectation of future sales and revenues,  customer plans may change due to many reasons, demand for Avivagens products may not continue to grow and could decline, Avivagens products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds, in each case due to many factors, many of which are outside of Avivagens control.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagens most recent managements discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.

Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164
Website: www.avivagen.com

Release – Kratos Receives Approximate $50 Million Single Award Sole Source High Performance Jet Drone System Related IDIQ Contract


Kratos Receives Approximate $50 Million, Single Award, Sole Source High Performance Jet Drone System Related IDIQ Contract

 

SAN DIEGO
Sept. 29, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that its 
Kratos Unmanned Aerial Systems division (KUAS) has recently received an approximate 
$50 million, single award, sole source, high performance jet drone system related Indefinite Delivery, Indefinite Quantity (IDIQ) contract from a 
United States Government Agency.  KUAS is the industry leader in the rapid design, manufacture and delivery of affordable, high performance jet drone systems. Work under this contract award will be performed as funded task orders are issued by the customer at secure Kratos facilities and customer locations.  Due to customer related, competitive, security, and other considerations, no additional information will be provided.

Steve Fendley, President of KUAS, said, “The Kratos team did an outstanding job working in partnership with this critical customer, addressing their needs and requirements and successfully negotiating this single award, sole source IDIQ contract.  We expect this contract to be fully funded over the contract’s multi-year period of performance.”

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
investor@kratosdefense.com

Source: Kratos Defense & Security Solutions, Inc.

FenixOro Gold (FDVXF) – Initial Phase 2 Drill Results Underscore Expanding Resource Potential

Wednesday, September 29, 2021

FenixOro Gold (FDVXF)
Initial Phase 2 Drill Results Underscore Expanding Resource Potential

FenixOro Gold Corp is a Toronto based company acquiring and exploring high grade gold projects in Colombia. The company’s flagship Abriaqui Project is the nearest exploration project to Continental Gold’s Buritica Mine.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Higher grades and wider widths. Assay results were received for the first three holes, along with partial results for the fourth, from the initial Phase 2 infill drill holes in the Northwest Vein Corridor (NWC) of the Abriaqui gold project. Drilling intersected a new high grade vein called Cascada which returned 1.3 meters grading 23.23 grams of gold per tonne and is part of a newly defined trend of at least 4 new veins. Three main veins in the northwest corridor revealed an increase in average grade and thickness.

    Increasing resource potential expectations.  Based on a small sample of drilling data from the Phase 1 drilling program, management estimated resource potential of 1.6 million to 2.4 million gold ounces. The company’s current resource model, incorporates only 4 of the 120 mapped veins on the project. Following the Phase 2 program, formal resource-definition drilling may begin in the NWC to define a …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – FenixOro Drills 23.2 gt Gold in Newly Discovered Cascada Vein


FenixOro Drills 23.2 g/t Gold in Newly Discovered Cascada Vein, Significantly Increases Resource Potential on Northwest Corridor at Abriaqui Gold Deposit

 

TORONTO, Sept. 28, 2021 (GLOBE NEWSWIRE) — FenixOro Gold Corp (CSE:FENX, OTCQB:FDVXF, Frankfurt:8FD) is pleased to announce that following lengthy delays caused by Covid 19-related issues in the Lima Peru lab, final assays have been received for the first three holes, along with partial results for the fourth, from the initial Phase 2 infill drill holes on the Northwest Vein Corridor (NWC) of the Abriaqui gold deposit. These results significantly increase the Company’s previously stated potential resource expectations and assumptions (see press release dated March 19, 2021).

Highlights include:

  • New high grade “Cascada” vein intersected 1.3m @ 23.23 g/t gold and is part of a newly defined WNW trend of at least four veins (see Figure 1)
  • Three main veins in the northwest corridor have an increase in average grade x thickness values 55%, 25%, and 20% higher than in previous resource potential estimates
  • Three new veins intersected deeper mineralization including 1.3m @ 19.47 g/t gold
  • Hole 14, currently in progress, is targeting mineralization up to 250 meters below the deepest drill intercept to date
  • The current resource model incorporates only 4 of the 120 known, mapped veins on the project. New data from Phase 2 drilling will allow the Company to incorporate 10 or more vein structures
  • Preparation underway for maiden drilling in the highly prospective southeastern license (see press release dated May 10, 2021)
  • Eight and ten veins respectively intersected in holes P010 and P012 (a re-drill of P011 which was lost)

FenixOro VP Exploration Stuart Moller commented, “We are extremely pleased with these first results of the NWC infill drill program as the higher average grades and thicknesses significantly increase resource potential on previously modeled veins. Our understanding of the Santa Teresa “vein” is also becoming much more clear: it is really a series of parallel veins within a corridor up to 15 meters wide, flanked and separated by a variably developed zone of veinlets and stockwork mineralization.”

Mr. Moller continued: “It was a significant surprise that we intersected four new veins within 150 meters of previous drill holes. The high grade Cascada vein and three new veins in the bottom of P012 add significantly to resource potential and more work is being done to include these in our formal model. Following this Phase 2 program we should be in a position to begin formal resource-definition spaced drilling on the NWC with the goal of defining a maiden resource on as many as ten veins, an increase from the four that are currently being modelled. Preparation is also underway to begin the first drill holes in the highly prospective southeastern block.”

New WNW Trending Vein Structure Identified
The newly designated “Cascada” vein was cut in P013. The intersection was 1.3m @ 23.23 g/t gold. It is different from most other veins at Abriaqui in that it has a low content of sulfides, low silver, and contains visible gold. Cascada appears to be part of a family of at least four veins which trend 290 degrees. These veins have not been mapped on surface and are known only from underground workings and the new intersection in P013. They appear intermittently between the major veins of the NWC which trend 315 degrees (Figure 1). Their geometry is not well enough understood to justify individual longitudinal sections at this point, but they appear to have higher than project-average gold grade and they offer significant upside potential to be evaluated in future drilling.

Three additional new veins were discovered in the bottom of hole P012. This “footwall series” of veins averages 1.5m in thickness with gold grades up to 19.47 g/t. (Table 2). These too are not yet well-understood geometrically and represent additional potential which will require deeper drilling to define.

Four plus holes have been drilled in Phase 2 for 2575 meters with a project total of 6604 meters in 14 holes (Table 1, Figure 1). P010 – P013 were drilled from the same pad as P001 as part of an infill program to begin the resource definition program on the northwest trending vein corridor (NWC). Holes were drilled at -45 degrees except for P012 and P014 which are angled at -65 degrees for deeper tests of the system. P011 was lost at 136 meters and P012 is a re-drill of that hole.

Table 2 highlights the principal gold-bearing intercepts in NWC drilling to date including newly reported values for P010 – P012 and the upper part of P013. P010 was drilled to the west to cover the gap between P001 and P005 and eight significant veins were intersected. P012 was drilled at a steeper angle to test the same vein package at depth. Ten veins were intersected with the deepest still carrying high grade at the 1540 meter elevation which matches the deepest drilled mineralization in the district to date. Hole P014 (in progress) is projected to intersect the deepest veins in the NWC at the 1300 meter elevation.

Table 1: 

Figure 1: 

Table 2: 

Resource Development Progress
Though no formal resource calculation has been done in the project area, FenixOro presented a series of longitudinal sections supporting an early estimate of resource potential on four veins in the Press Release of March 19, 2021. The three of those sections which are part of the NWC are updated here with the new drill data and results of recent underground channel sampling. The Santa Teresa Vein system is the largest in the NWC. It is really a series of parallel veins within a corridor up to 15 meters wide flanked and separated by a variably developed zone of veinlets and stockwork mineralization. As seen in Figure 2, we now have five data points defining the potential resource block including four drill holes and a channeled interval from a mine working (see Press Release of August 6, 2021). The average grade times thickness parameter (GxT, Table 3) for these points is 53% greater than in the March 19 estimate and our degree of confidence in that number is significantly higher given the larger data set.

Figure 3 shows the Orquidea Vein in longitudinal section (NWC4 vein in the earlier presentation). The four drill intersections average 1.86m @ 12.68 g/t gold with a GxT 24% higher than that used in the initial assessment. Figure 4 presents the Romperopa 1 Vein (NWC5). The three intersections average 2.45m @ 8.32 g/t gold with a GxT 20% higher than the previous value.

The yellow minimum resource potential blocks in each section are defined by the position of the drill holes and channeled interval, samples in shallow mine workings, the Cascada Fault on the southeast, and the 1500m elevation at depth. Areas of additional potential are shown with red arrows. These will be evaluated with ongoing step-out drilling laterally and at depth as indicated by the projected pierce points of the remaining Phase 2 drill holes shown in blue. The mineralization is open at depth below 1540m and the expectation is that there is significant room for resource growth downward on all veins. Hole P014 (in progress) is projected to intersect the deeper veins at about the 1300m elevation. Hole P009 from Phase 1 and visual inspection of the lower part of P013 (assays pending) indicate that the veins of the NWC continue to the southeast of the Cascada Fault and there is excellent potential for multiple mineralized veins in that direction.

Phase 2 drilling will continue with at least two more infill holes on the NWC, one infill hole on the EWC, and 4-5 holes in the highly prospective southeast license. The program is scheduled to continue into Q1 2022.

Figure 2: 

Figure 3: 

Figure 4: 

Table 3: 

Technical Information
Stuart Moller, Vice President Exploration and Director of the Company and a Qualified Person for the purposes of NI 43-101 (P.Geo, British Colombia), has prepared or supervised the preparation of the technical information contained in this press release. Mr. Moller has more than 40 years of experience in exploration for precious and other metals including ten in Colombia and is a Fellow of the Society of Economic Geologists.

Drill core sampling is done in accordance with industry standards. The HQ and NQ diameter core is sawed, and half core samples are submitted to the laboratory. The other half core along with laboratory coarse reject material and sample pulps are stored in secure facilities on site and/or in the sample prep lab. Following strict chain of custody protocols, the samples are driven to the ISO 17025:2017 certified ALS Laboratory sample preparation facility in Medellin and ALS ships the prepared pulps to their assay laboratory in Lima, Peru. Blanks, duplicates, and certified reference standards totaling 15% of the total samples are inserted into the sample stream. To date, no material quality control issues have been detected. Gold is analyzed by fire assay with 50 gram charges for grades in excess of 10 grams per tonne and the additional elements are analyzed by ICP with appropriate follow-up for over- limits.

Reported grade intervals are calculated using uncut gold values. Maximum sample length is one meter. Intervals which include multiple samples are calculated using the full geologic interval of mineralization and are not subject to specific rules for cutoff grades and internal low grade. As such, quoted thickness and grade of these intervals do not necessarily represent optimized economic intervals in a potential future mine. Reported sample and interval widths are based on lengths of individual samples in core and do not necessarily represent true widths of mineralization. True widths will sometimes be less than the quoted interval lengths.

There are currently no NI 43-101 compliant resources or reserves in the project area. The analysis of drill results is intended to estimate the potential for future resources which will require significant additional drilling to define.

The comparison between Abriaqui and the nearby Buritica project is meant only to indicate the similarities between the two in terms of geological setting. FenixOro does not imply that exploration results and/or economic characteristics of a potential future mine at Abriaqui will be similar to those seen at Buritica.

About FenixOro Gold Corp.
FenixOro Gold Corp is a Canadian company focused on acquiring and exploring gold projects with world class exploration potential in the most prolific gold producing regions of Colombia. FenixOro’s flagship property, the Abriaqui project, is located 15 km west of Continental Gold’s Buritica project in Antioquia State at the northern end of the Mid-Cauca gold belt, a geological trend which has seen multiple large gold discoveries in the past 10 years including Buritica and Anglo Gold’s Nuevo Chaquiro and La Colosa. As documented in “NI 43-101 Technical Report on the Abriaqui project Antioquia State, Colombia” (December 5, 2019), the geological characteristics of Abriaqui and Buritica are similar. The report also documents the high gold grade at Abriaqui with samples taken from 20 of the veins assaying greater than 20 g/t gold. Since the preparation of this report a Phase 1 drilling program has been completed at Abriaqui resulting in a significant discovery of a high grade, “Buritica style” gold deposit. A Phase 2 drilling program has recently commenced.

FenixOro’s VP of Exploration, Stuart Moller, led the discovery team at Buritica for Continental Gold in 2007-2011. At the time of its latest public report, the Buritica Mine contains measured plus indicated resources of 5.32 million ounces of gold (16.02 Mt grading 10.32 g/t) plus a 6.02 million ounce inferred resource (21.87 Mt grading 8.56 g/t) for a total of 11.34 million ounces of gold resources. Buritica began formal production in November 2020 and has expected annual average production of 250,000 ounces at an all-in sustaining cost of approximately US$600 per ounce. Resources, cost and production data are taken from Continental Gold’s “NI 43-101 Buritica Mineral Resource 2019-01, Antioquia, Colombia, 18 March, 2019″). Continental Gold was recently the subject of a takeover by Zijin Mining in an all-cash transaction valued at C$1.4 billion.

Forward Looking Information
This news release contains certain forward-looking information. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. Specifically, this news release contains forward looking information regarding the significance of Phase 1 drill results at the Abriaqui Project, conclusions as to resource potential derived from that data set, potential results of the Phase 2 drill program, and implied assumptions as to the potential future economic viability of the gold grades and vein thicknesses reported. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. Although FenixOro has no reason to believe otherwise, there can be no assurance that the Phase 2 drill program and potential future resource definition drilling will be completed as uncertainties exist related to future project financing and future environmental permitting. Although FenixOro has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be additional factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information.

FenixOro Gold Corp
John Carlesso, CEO
Email: info@FenixOro.com
Website: www.FenixOro.com
Telephone: 1-833-ORO-GOLD

Release – Allegiant Receives Final BLM Approval At Flagship Eastside Project, Increasing Permitted Area By 600 Percent


Allegiant Receives Final BLM Approval At Flagship Eastside Project, Increasing Permitted Area By 600%

 

also receives amended drilling permit for follow-up drilling at RECENT high-grade discovery AT EASTSIDE

Reno, Nevada /September 28, 2021 – Allegiant Gold Ltd. (“Allegiant” or the “Company”) (AUAU: TSX-V) (AUXXF: OTCQX) is very pleased to announce the receipt of two permits allowing for a significant expansion of drilling and operations at its Flagship Eastside Project (Inferred ounces of 1.4M Au and 8.7M Ag*) near the town of Tonopah, Nevada. The first permit expands the Plan-of-Operations (“PoO”) from the previous 600 acres to over 3,676 acres around the Original Pit Zone. The second permit received amends the existing drill target plan within the Original Pit Zone and will allow Allegiant to drill up to 14 new diamond core holes to test the recently discovered high-grade zone announced on May 26, 2021. Highlights of that announcement included:

  • Strong gold intercepts in Holes 239, 243, 244 and 245
  • Mineralization encountered in 7 of 9 holes
  • Significant silver in Holes 243 and 239
  • Hole 243 included 2.55 g/t Au over 147.8 metres (3.17 g/t Au over 117.3m)
  • Hole 239 included 111.3m of 1.45 g/t Au including 3.1 metres of 39 g/t at the bottom of the hole.
  • Hole 244 included 76 metres of mineralization with best intercept being 6.1m of 1.48 g/t Au
  • Hole 245 included 15.2 metres of 3.4 g/t Au from relatively shallow depths (177m)
  • Eastside remains open in all directions and at depth in both the Original Pit Zone and the Castle Zone

Peter Gianulis, CEO of Allegiant Gold, commented: “The receipt of the two permits is a major development that will allow us to further expand beyond the existing Original Pit Zone at Eastside as well as offset drilling around the recently discovered high-grade zone. We embarked on this expanded Plan-of-Operations over 18 months ago with the plan of testing geochemical and geophysical anomalies that have never been previously drilled. We look forward to executing our business plan which includes significant drilling.”

The newly approved PoO allows Allegiant to build new roads and access to 160 new drill sites to test gold, arsenic, and intense hydrothermal alteration zones continuing south and west of the existing resource for at least 2-3 km. It also allows Allegiant to drill geophysical anomalies on the pediment east of our existing resource which are interpreted to be rhyolite domes known to be key for hosting gold at Eastside. Allegiant plans to provide a comprehensive update on the business plan and the upcoming drilling in the near future.

*The updated resource estimate (“Updated Resource Estimate and NI 43-101 Technical Report, Eastside and Castle Gold-Silver Project Technical Report, Esmeralda County, Nevada”) was conducted by Mine Development Associates (“MDA”), a division of RESPEC of Reno, Nevada with an effective date of July 30, 2021. Contained pit-constrained Inferred Resources (cut-off grade of 0.15 g/t) of 1,090,000 Au ounces in 61,730,000 tonnes at 0.55 g/t Au and 8,700,000 Ag ounces at 4.4 g/t Ag at the Original Pit Zone and 314,000 Au ounces in 19,986,000 tonnes at 0.49 g/t Au at the Castle Area. In accordance with NI 43-101, the MDA Technical Report dated July 30, 2021, will be filed on SEDAR. This report builds on and supersedes the NI 43-101 reports of Ristorcelli (December 2016), Ristorcelli (July 2017) and Ristorcelli (January 2020) titled “Amended Updated Resource Estimate and NI 43-101 Technical Report, Eastside and Castle Gold-Silver Project, Esmeralda County, Nevada” prepared for Allegiant with an Effective Date of December 30, 2019.

See Eastside expanded permit area here:

Map 1: Expanded Permit Area Map
https://allegiantgold.com/site/assets/files/2209/eastside-expanded-permit-area-map.jpg

QUALIFIED PERSON

Andy Wallace is a Certified Professional Geologist (CPG) with the American Institute of Professional Geologists and is the Qualified Person under NI 43-101, Standards of Disclosure for Mineral Projects, who has reviewed and approved the scientific and technical content of this press release.

ABOUT ALLEGIANT

Allegiant owns 100% of 10 highly-prospective gold projects in the United States, 7 of which are located in the mining-friendly jurisdiction of Nevada. Four of Allegiant’s projects are farmed-out, providing for cost reductions and cash-flow. Allegiant’s flagship, district-scale Eastside project hosts a large and expanding gold resource and is located in an area of excellent infrastructure. Preliminary metallurgical testing indicates that both oxide and sulphide gold mineralization at Eastside is amenable to heap leaching.

ON BEHALF OF THE BOARD

Peter Gianulis
CEO

For more information contact:
Investor Relations
(604) 634-0970 or
1-888-818-1364
ir@allegiantgold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements and information contained in this press release constitute “forward-looking statements” within the meaning of applicable U.S. securities laws and “forward-looking information” within the meaning of applicable Canadian securities laws, which are referred to collectively as “forward-looking statements”. The United States Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements.Allegiant Gold Ltd.’s (“Allegiant”) exploration plans for its gold exploration properties, the drill program at Allegiant’s Eastside project, the preparation and publication of an updated resource estimate in respect of the Original Zone at the Eastside project, Allegiant’s future exploration and development plans, including anticipated costs and timing thereof; Allegiant’s plans for growth through exploration activities, acquisitions or otherwise; and expectations regarding future maintenance and capital expenditures, and working capital requirements. Forward-looking statements are statements and information regarding possible events, conditions or results of operations that are based upon assumptions about future economic conditions and courses of action. All statements and information other than statements of historical fact may be forward-looking statements. In some cases, forward-looking statements can be identified by the use of words such as “seek”, “expect”, “anticipate”, “budget”, “plan”, “estimate”, “continue”, “forecast”, “intend”, “believe”, “predict”, “potential”, “target”, “may”, “could”, “would”, “might”, “will” and similar words or phrases (including negative variations) suggesting future outcomes or statements regarding an outlook. Such forward-looking statements are based on a number of material factors and assumptions and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or industry results, to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on forward-looking statements contained in this press release. Some of the known risks and other factors which could cause actual results to differ materially from those expressed in the forward-looking statements are described in the sections entitled “Risk Factors” in Allegiant’s Listing Application, dated January 24, 2018, as filed with the TSX Venture Exchange and available on SEDAR under Allegiant’s profile at www.sedar.com. Actual results and future events could differ materially from those anticipated in such statements. Allegiant undertakes no obligation to update or revise any forward-looking statements included in this press release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Source: Allegiant Gold Ltd.

Release – Genprex Strengthens Management Team with Appointments of Industry Leaders


Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer

 

Seasoned innovative drug development executives bolster leadership with relevant domain expertise as Company advances key Acclaim-1 and Acclaim-2 clincial trials of REQORSA systemic gene therapy in non-small cell lung cancer and works to expand technology pipeline

AUSTIN, Texas — (September 28, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of Chief Medical Officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of Chief Manufacturing and Technology Officer.  Drs. Berger and Kumar will report to  Rodney Varner, Chief Executive Officer of Genprex. 

“It is my priviledge and pleasure to welcome Mark and Hemant to our management team.  Their collective accomplishments and deep domain expertise in clinical development and gene therapy manufacturing, respectively, will be of great value as they help guide Genprex and advance our important Acclaim-1 and Acclaim-2 clinical trials in non-small cell lung cancer this year,” stated Mr. Varner.  “As we continue to make progress with these studies, and to expand our technology pipeline, it is more important than ever to have medical affairs and manufacturing in such capable hands.”

“I am delighted to join the growing team at Genprex, confident that my experience designing and managing pivotal clinical trials in oncology will provide valuable insight and oversight for Genprex’ novel gene therapy pipeline,” commented Dr. Berger. “Advancing the first systemic gene therapy in oncology is  a uniquely exciting opportunity to transform cancer care for patients with limited treatment options and I am looking forward to working with Genprex’ leadership team to help develop this new approach to cancer treatment.”  

“I am delighted to join the management team at Genprex and to work alongside this group of seasoned executives to realize the potential for its novel systemic gene therapy to improve outcomes for cancer patients,” noted Dr. Kumar.  “I am eager to apply my expertise and technical background in accelerated development of innovative biologics and advanced cell and gene therapies to support Genprex’ already impressive work and drive its technologies to commercialization.” 

About Mark S. Berger

Dr. Berger is an oncologist and senior executive with 25 years of biotech and pharmaceutical company experience in the development of oncology therapeutics.  He has successfully brought two drugs through the regulatory process to approval and excels in strategic development, team management and collaborative leadership. Dr. Berger joins Genprex from Actinium Pharmaceuticals, Inc. where since January 2017 he served as Chief Medical Officer and was responsible for clinical strategy and development of radioisotope-labeled antibodies for therapy in oncology, including the Company’s Phase 3 SIERRA trial.  Before that, Dr. Berger was Senior Vice President-Clinical Research at Kadmon Corporation from 2013 through 2017, where he led all aspects of the company’s new drug development, including clinical trial design and management of the oncology programs in non-small cell lung cancer and breast cancer, among others. 

Prior to that, Dr. Berger was Chief Medical Officer of Deciphera Pharmaceuticals from June 2011 to September 2013. Before Deciphera, Dr. Berger was Vice President for Clinical Development at Gemin X Pharmaceuticals, where he led the clinical strategy, design and management of clinical trials for two novel oncology agents including obatoclax. Based on the results of a randomized Phase 2 clinical trial of obatoclax, Gemin X was acquired by Cephalon in March of 2011. Before his work with biotechnology companies, Dr. Berger held key positions in two global pharmaceutical companies. Dr. Berger previously served as Group Director, Medicine Development Centre-Oncology for GlaxoSmithKline. In this position Dr. Berger managed the development of Tykerb (lapatinib) in lung and breast cancer where he designed and led two Phase 2 clinical trials before planning and leading a 399 patient pivotal Phase 3 trial that resulted in the FDA approval of Tykerb in breast cancer. In addition, he managed the Lapatinib Expanded Access Program that enrolled over 4000 patients on a global basis. Dr. Berger began his career in drug development at Wyeth Research where he led the planning and execution of the pivotal Phase 2 trial for Mylotarg, which was the first antibody targeted chemotherapy agent. He presented the Mylotarg clinical data at the FDA’s Oncology Drug Advisory Committee meeting, after which Mylotarg received accelerated FDA approval for patients with relapsed AML.

Dr. Berger holds a B.A. in biology from Wesleyan University and a M.D. from the University of Virginia School of Medicine. He did his Hematology/Oncology fellowship at the University of Pennsylvania, where he was an Assistant Professor of Medicine, and also was a Research Fellow at the Ludwig Institute for Cancer Research and the Imperial Cancer Research Fund, both in London. Dr. Berger is board certified in internal medicine, hematology and medical oncology. 

About Hemant Kumar, Ph.D., CPM, EMBA

Dr. Kumar is a recognized global expert in Chemistry, Manufacture and Controls (CMC) Technical Development and GMP manufacturing.  He has a greater than 25-year track record leading global CMC and regulatory approval strategy for accelerated development of innovative vaccines, biologics, advanced cell & gene therapy drug process and product development (Ph1 to Ph3 and commercialization) under current GMP, and licensing processes. Dr. Kumar joins Genprex from Arcturus Therapeutics, Inc., where he served as Strategic Advisor and then Vice President, Global Head of Manufacturing, Supply Chain, and Strategy.  Prior to that, Dr. Kumar was Vice President of CMC Technical Development & Manufacturing Operations at Oncoimmune Therapeutics, Inc., a private company that was acquired by Merck & Co. during his tenure there.  Before that, he was Vice President, Head of Global Process Sciences and Clinical Manufacturing Operations at Rentscher BioPharma, SE.  Previous to that, Dr. Kumar was with Anaptysbio, Inc., where he served as Senior Vice President, Head of Global CMC, Technical Development and Manufacturing Operations.   Before that, Dr. Kumar held senior level positions of increasing manufacturing and technical operations leadership in global biopharmaceutical companies including Merck & Co., Inc.,  Sanofi Genzyme, Inc., Lonza Biologics, Inc., Sanofi Pasteur, Janssen Biotech ( a Johnson & Johnson company) and Wyeth Lederle Vaccines, Inc.

Dr. Kumar earned his Ph.D. in Biochemistry at J.N. Medical College, Aligarth India through a collaboration with the U.S. National Institutes of Health. He holds a graduate certificate in Project Management from Lehigh University School of Management.  Dr. Kumar has conducted postdoctoral and research scientist fellowships at Yale University School of Medicine, the University of Rhode Island and the Center for Disease Control and Prevention’s Center for Infectious Diseases.  He holds professional affilations with the American Chemical Society, American Association for the Advancement of Science, Americal Society for Microbiology and the International Society of Pharmaceutical Engineers.  

Inducement Grants

The Company has granted 550,000 options to Dr. Berger at an exercise price equal to $2.85, the closing price of our common stock on September 27, 2021, the date of grant. While these options were not granted under Genprex’s 2018 Equity Incentive Plan (the “Plan”), the awards will incorporate the terms of the Plan.  The options vest as to one-third of the shares over the next three years and are exercisable for a period of ten years subject to continued service to the Company.

The Company has granted 400,000 options to Dr. Kumar at an exercise price equal to $2.85, the closing price of our common stock on September 27, 2021, the date of grant. While these options were not granted under the Plan, the awards will incorporate the terms of the Plan.  The options vest as to one-third of the shares over the next three years and are exercisable for a period of ten years subject to continued service to the Company.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso.

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes;  Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.

(877) 774-GNPX (4679)

Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) ext. #2

investors@genprex.com

Media Contact

Genprex Media Relations

Anne Marie Fields

(877) 774-GNPX (4679) ext. #3

afields@rxir.com

Stem Holdings (STMH)(STEM:CA) – California E-Commerce and Delivery Expansion

Tuesday, September 28, 2021

Stem Holdings (STMH)(STEM:CA)
California E-Commerce and Delivery Expansion

Stem Holdings Inc is engaged in the purchasing, improving, and leasing of properties and finance assets which are operated by third parties and are used for the cultivation and retail sale of marijuana. Its properties includes 42nd Street, and Mulino Farm which are used for agriculture. The company generates its revenue in the form of rental income from tenants.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    California Expansion. On the heels of last weeks expansion in Oregon, Driven by Stem has received a non-storefront license to open a distribution hub in Mendota, located in the county of Fresno, enabling it to provide better service to consumers with its Budee e-commerce platform in four key counties in Northern California, home to 2.3 million residents.

    Benefits.  The expansion is expected to drive topline sales with greater efficiency, as the Company anticipates savings of up to $1 million in operating expenses, with significant savings in gross receipt taxes. The Company plans for the Mendota hub to become operational in October through a new 2,000 square foot facility, which will be dedicated to delivery service in 60 minutes or less …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Item 9 Labs (INLB) – Expanding Unity Rd. Footprint

Tuesday, September 28, 2021

Item 9 Labs (INLB)
Expanding Unity Rd. Footprint

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by 650,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Agreements. Item 9 Labs announced continued development of its cannabis dispensary franchise brand, Unity Rd., across the Northeastern United States with new signed agreements for development in New Jersey and Virginia and the signing of a lease for the first Unity Rd. dispensary in Maine by an existing partner. Unity Rd. has multiple agreements signed with more than 15 entrepreneurial groups who are in various stages of development across eight states.

    New Jersey.  Adult use was approved by voters in November 2020 and in August regulators approved initial rules for the program that will set up the state’s retail market. The New Jersey market is projected to hit around $750 million of sales in the first full year growing to $2.1 billion in the fourth year …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Grindrod Shipping (GRIN) – Secondary Offering Improves Public Market Float

Tuesday, September 28, 2021

Grindrod Shipping (GRIN)
Secondary Offering Improves Public Market Float

Grindrod Shipping, originated in South Africa with roots dating back to 1910. The company is based in Singapore, with offices around the world including, London, Durban, Cape Town, Tokyo and Rotterdam. Its primary listing is on Nasdaq and secondary listing on the JSE.

Grindrod Shipping owns and operates a diversified fleet of owned, long-term chartered and joint-venture dry-bulk and liquid-bulk vessels across the globe.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Secondary offering enhances trading liquidity.  Grindrod Limited, the former parent, sold 1.84 million shares last week in a secondary offering at $13.50/share pursuant to a F-3 filing dated August 23rd. While the offering was priced at a 14% discount to the previous closing price, the stock rebounded quickly and closed yesterday ~13% above the offering price. We view the offering favorably since the public market float increased to 13.1 million shares, or 68%, and trading liquidity is likely to improve.

    No change to current 2021-2 EBITDA estimates and variable dividend policy on horizon.  Our 4Q2021 dividend estimate is $0.61/share, including cash of $0.54/share and buybacks of $0.07/share. As highlighted in recent notes, the variable dividend will consist of a combo of buybacks and cash. As of August 30th, 91,871 shares were bought back at an average $14.87/share so total dividend will include …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.